Prospects for the targeted treatment research of TSHR and IGF-1R in Graves disease and Graves ophthalmopathy / 中华核医学与分子影像杂志
Chinese Journal of Nuclear Medicine and Molecular Imaging
;
(6): 434-439, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-869182
ABSTRACT
Anti-thyroid drug (ATD), radioactive iodine (RAI) and thyroidectomy are treatment options for Graves disease (GD). Treatment strategies for Graves ophthalmopathy (GO) patients include thyroid function control, oral or intravenous corticosteroids, orbital radiotherapy or orbital decompression surgery. However, current treatments for GD and GO are also less ideal because they target the signs and symptoms rather than the pathogenic mechanisms. The development of treatment strategies that targeting the thyroid-stimulating hormone receptor (TSHR) or insulin-like growth factor 1 receptor (IGF-1R) alone or in combination may yield effective and better tolerated treatments for GD and GO. This paper reviews the progress and limitations of the 2 methods.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Nuclear Medicine and Molecular Imaging
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS